Highly sensitive next-generation sequencing-based MRD testing will identify eligible patients with T-cell malignancies ...
Solstice Advanced Materials ("Solstice" or the "Company") and Element Solutions ("Element") today announced that they have entered into a definitive agreement for Solstice to acquire Element in a ...
Is this a sign consumerism is out of control?
Daniel Ermann, MD, discusses his approach to treatment sequencing in patients with chronic lymphocytic leukemia who aged 80 ...
The treatment landscape of chronic lymphocytic leukaemia has undergone a revolution in the past decade. Highly effective ...
From sequencing decisions to economics of care, Adam Kittai, MD, offers a wide-ranging look at top unresolved questions in CLL treatment today. He also explored when a triplet regimen—acalabrutinib, ...
Back from ASH 2025, Dr Suchitra Sundaram reports on notable frontline CLL data. Time‑limited pirtobrutinib combined with venetoclax and obinutuzumab produced high rates of undetectable minimal ...
Final results of the CLL14 study reveal the efficacy of 1-year venetoclax-obinutuzumab therapy for chronic lymphocytic leukemia. Median progression-free survival (PFS) was 76.6 months in the VO arm vs ...
National security, unlocked. Each Thursday, host Mary Louise Kelly and a team of NPR correspondents discuss the biggest national security news of the week. With decades of reporting from battlefields ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results